首頁 > 市場調查報告書 > 製藥

荷爾蒙避孕藥市場規模、佔有率和成長分析（按產品、荷爾蒙、年齡、最終用戶和地區分類）：產業預測（2026-2033 年）

市場調查報告書

商品編碼

1896865

荷爾蒙避孕藥市場規模、佔有率和成長分析（按產品、荷爾蒙、年齡、最終用戶和地區分類）：產業預測（2026-2033 年）

Hormonal Contraceptive Market Size, Share, and Growth Analysis, By Product, By Hormones, By Age, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球荷爾蒙避孕藥市場規模將達到 201.1 億美元，到 2025 年將達到 209.5 億美元，到 2033 年將達到 291.2 億美元，預測期（2026-2033 年）的複合年成長率為 4.2%。

全球荷爾蒙避孕藥市場正經歷顯著擴張，這主要得益於人們對避孕方法的認知和接受度不斷提高，以及對有效計劃生育方案需求的日益成長。雖然這些方法能有效預防懷孕，但並不能性行為感染感染（STI），因此仍需採取其他預防措施。消費者越來越傾向選擇口服避孕藥，尤其是複方口服避孕藥。由於其高效性和易用性，複方口服避孕藥佔據了市場主導地位。然而，僅含黃體素的避孕藥也已成為一個重要的細分市場，並有望加速成長，因為其副作用極小，且適用於無法耐受雌激素的女性。這種動態的市場格局反映了偏好的轉變以及對可靠生殖健康方案的持續追求。

全球荷爾蒙避孕藥市場促進因素

全球荷爾蒙避孕藥市場的成長主要得益於人們對避孕作為重要計劃生育手段的認知和接受度不斷提高。隨著人口持續成長，尤其是在發展中地區，人們對有效避孕方法的需求日益迫切，以幫助夫妻有效控制家庭規模和生育間隔。這種日益成長的需求導致荷爾蒙避孕藥的使用量顯著增加，研究表明，荷爾蒙避孕藥在預防意外懷孕方面非常有效。此外，荷爾蒙避孕藥的便利性和可逆性使其成為尋求可靠計劃生育方法人士的理想選擇。

全球荷爾蒙避孕藥市場受到壓制

全球荷爾蒙避孕藥市場面臨嚴峻挑戰，社會和文化因素阻礙了女性獲得避孕服務。在不同的文化和社會中，避孕往往被視為負面行為，某些宗教信仰甚至強烈反對使用避孕措施。此外，許多地區對避孕方法的認知和教育不足也導致需求低落。這些問題嚴重限制了市場成長，尤其是在文化規範和社會態度對避孕決策有顯著影響的地區。因此，克服這些障礙對於提高全球荷爾蒙避孕藥的可及性和接受度至關重要。

全球荷爾蒙避孕藥市場趨勢

全球荷爾蒙避孕市場正經歷著長效可逆避孕方法（LARCs）的顯著轉變，例如子宮內避孕器（IUD）和植入式。這反映出消費者對高效率、長效避孕方案的需求日益成長。 LARCs具有顯著優勢——高效且長期維護成本低——使其成為追求可靠性和便利性的女性的理想選擇。這趨勢在年輕女性中尤其明顯，除了重視避孕效果外，她們也十分重視產品的易用性。因此，生產商正致力於拓展LARCs產品線，改善產品獲取途徑，並加大教育投入，以提高大眾對這些避孕方法的認知度並推廣其使用。

拜耳股份公司（德國）
輝瑞公司（美國）
默克公司（美國）
強生公司（美國）
艾伯維公司（美國）
梯瓦製藥工業股份有限公司（以色列）
邁蘭公司（美國）
Viatris公司（美國）
Organon & Co.（美國）
Mithra製藥（比利時）
Agile Therapeutics, Inc.（美國）
Mayne Pharma Group Limited（澳洲）
Afaxys公司（美國）
Pregna 國際有限公司（印度）
魯賓製藥公司（印度）
西普拉有限公司（印度）
太陽製藥工業有限公司（印度）
Piramal Enterprises Limited（印度）

結論與建議

簡介目錄

Product Code: SQMIG35I2132

Global Hormonal Contraceptive Market size was valued at USD 20.11 Billion in 2024 and is poised to grow from USD 20.95 Billion in 2025 to USD 29.12 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

The global market for hormonal contraceptives is experiencing significant expansion, driven by heightened awareness and acceptance of contraceptive options along with a rising demand for effective family planning solutions. While these methods excel at preventing pregnancy, they do not offer protection against sexually transmitted infections (STIs), necessitating additional protective measures. Consumers are increasingly opting for oral contraceptives, particularly combination pills, which dominate the market due to their efficacy and ease of use. However, progestin-only pills are emerging as a strong segment, anticipated to witness accelerated growth owing to their minimal side effects and compatibility for women unable to use oestrogen. This dynamic landscape reflects shifting preferences and the ongoing pursuit of reliable reproductive health options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hormonal Contraceptive market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hormonal Contraceptive Market Segments Analysis

Global Hormonal Contraceptive Market is segmented by Product, Hormones, End User, Age and region. Based on Product, the market is segmented into Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings and Transdermal Patches. Based on Hormones, the market is segmented into Progestin Only Contraceptive and Combined Hormonal Contraceptive. Based on Age, the market is segmented into 15-24 Years, 25-34 Years, 35-44 Years and Above 44 Years. Based on End User, the market is segmented into Hospitals, Household and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is significantly driven by the heightened awareness and acceptance of contraception as a vital tool for family planning. As population growth continues, especially in developing regions, the demand for effective birth control solutions becomes increasingly pressing to help couples effectively manage family size and spacing. This burgeoning need has resulted in a notable rise in the utilization of hormonal contraceptives, which are recognized for their high efficacy in preventing unintended pregnancies. Additionally, their convenience and reversibility make hormonal contraceptives an attractive option for those seeking reliable family planning methods.

Restraints in the Global Hormonal Contraceptive Market

The global hormonal contraceptive market faces notable challenges stemming from social and cultural factors that hinder women's access to contraceptives. In various cultures and societies, contraception is often perceived unfavorably, with certain religious beliefs actively opposing its use. Additionally, limited awareness and education regarding contraceptive options further contribute to decreased demand in numerous regions. These issues significantly restrict market growth, particularly in areas where cultural norms and societal attitudes heavily influence decisions about contraceptive use. As a result, overcoming these barriers is crucial for enhancing accessibility and acceptance of hormonal contraceptives worldwide.

Market Trends of the Global Hormonal Contraceptive Market

The global hormonal contraceptive market is witnessing a notable shift towards long-acting reversible contraceptives (LARCs) like intrauterine devices (IUDs) and subdermal implants, reflecting a growing consumer preference for effective, long-term birth control solutions. LARCs offer significant advantages, including high efficacy rates and minimal maintenance over extended periods, making them appealing to women seeking reliable and convenient contraceptive options. This trend is particularly prevalent among younger demographics, who are prioritizing not only effectiveness but also ease of use. Consequently, manufacturers are focusing on expanding LARC offerings, enhancing accessibility, and investing in educational initiatives to promote awareness and utilization of these options.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Hormonal Contraceptive Market Size by Product & CAGR (2026-2033)

Market Overview
Oral Contraceptive Pills
Injectable Birth Control
Emergency Contraceptive Pills
Vaginal Rings
Transdermal Patches

Global Hormonal Contraceptive Market Size by Hormones & CAGR (2026-2033)

Market Overview
Progestin Only Contraceptive
Combined Hormonal Contraceptive

Global Hormonal Contraceptive Market Size by Age & CAGR (2026-2033)

Market Overview
15-24 Years
25-34 Years
35-44 Years
Above 44 Years

Global Hormonal Contraceptive Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Household
Clinics

Global Hormonal Contraceptive Market Size & CAGR (2026-2033)

North America (Product, Hormones, End User, Age)
- US
- Canada
Europe (Product, Hormones, End User, Age)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Hormones, End User, Age)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Hormones, End User, Age)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Hormones, End User, Age)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Organon & Co. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mithra Pharmaceuticals (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agile Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mayne Pharma Group Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Afaxys, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pregna International Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Pharmaceuticals Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Enterprises Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments